Concepedia

Jonathan Zalevsky

JZ

Statistics

Publications

47

Citations

5.1K

H-Index

28

Active since

1999

Affiliations

Nektar Therapeutics (United States)(Current)

The University of Texas MD Anderson Cancer Center

Xencor (United States)

Providence Portland Medical Center

Yale University

Jonathan Zalevsky is an author at Nektar Therapeutics (United States) specializing in immunology, immunotherapy, and cancer immunotherapy.

ORCID

Publications per year

1999–2024

47

Publications

47

β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2

Kathryn DeFea, Jonathan Zalevsky, Mark S. Thoma et al. · The Journal of Cell Biology · 2000 · 813 citations · Full text

, , +17

Enhanced antibody half-life improves in vivo activity

Jonathan Zalevsky, Aaron K. Chamberlain, Holly M. Horton et al. · Nature Biotechnology · 2010 · 644 citations · Full text

, , +12

JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes

Matthew Nguyen, Hiroaki Satoh, Svetlana Favelyukis et al. · Journal of Biological Chemistry · 2005 · 402 citations · Full text

, , +17

Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants

Paul M. Steed, Malú G. Tansey, Jonathan Zalevsky et al. · Science · 2003 · 259 citations

, , +17

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel et al. · Cancer Discovery · 2020 · 238 citations · Full text

, , +17

1–5 of 47